100 related articles for article (PubMed ID: 30851173)
21. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients.
Schmeding M; Neumann UP; Puhl G; Bahra M; Neuhaus R; Neuhaus P
Liver Transpl; 2007 May; 13(5):687-92. PubMed ID: 17457911
[TBL] [Abstract][Full Text] [Related]
22. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables.
Duarte-Rojo A; Veldt BJ; Goldstein DD; Tillman HL; Watt KD; Heimbach JK; McHutchison JG; Poterucha JJ; Vargas-Vorackova F; Charlton MR
Transplantation; 2012 Jul; 94(2):197-203. PubMed ID: 22766768
[TBL] [Abstract][Full Text] [Related]
23. Risk Factors and Clinical Course for Liver Steatosis or Nonalcoholic Steatohepatitis After Living Donor Liver Transplantation.
Miyaaki H; Miuma S; Taura N; Shibata H; Sasaki R; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
Transplantation; 2019 Jan; 103(1):109-112. PubMed ID: 29894414
[TBL] [Abstract][Full Text] [Related]
24. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course.
Gallegos-Orozco JF; Yosephy A; Noble B; Aqel BA; Byrne TJ; Carey EJ; Douglas DD; Mulligan D; Moss A; de Petris G; Williams JW; Rakela J; Vargas HE
Liver Transpl; 2009 Dec; 15(12):1872-81. PubMed ID: 19938138
[TBL] [Abstract][Full Text] [Related]
25. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
[TBL] [Abstract][Full Text] [Related]
26. Donor-Model for End-Stage Liver Disease and donor-recipient matching in liver transplantation.
Vitale A; Ramirez Morales R; dalla Bona E; Scopelliti M; Zanus G; Neri D; d'Amico F; Gringeri E; Russo F; Burra P; Angeli P; Cillo U
Transplant Proc; 2011 May; 43(4):974-6. PubMed ID: 21620029
[TBL] [Abstract][Full Text] [Related]
27. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
Selzner N; Girgrah N; Lilly L; Guindi M; Selzner M; Therapondos G; Adeyi O; McGilvray I; Cattral M; Greig PD; Grant D; Levy G; Renner EL
Liver Transpl; 2008 Dec; 14(12):1778-86. PubMed ID: 19025914
[TBL] [Abstract][Full Text] [Related]
28. Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsilon4 carriers: relationship with the blood lipid profile.
Fabris C; Toniutto P; Bitetto D; Minisini R; Smirne C; Caldato M; Pirisi M
Liver Int; 2005 Dec; 25(6):1128-35. PubMed ID: 16343062
[TBL] [Abstract][Full Text] [Related]
29. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.
Berres ML; Trautwein C; Schmeding M; Eurich D; Tacke F; Bahra M; Neuhaus P; Neumann UP; Wasmuth HE
Hepatology; 2011 Feb; 53(2):596-603. PubMed ID: 21274880
[TBL] [Abstract][Full Text] [Related]
30. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
Burak KW; Kremers WK; Batts KP; Wiesner RH; Rosen CB; Razonable RR; Paya CV; Charlton MR
Liver Transpl; 2002 Apr; 8(4):362-9. PubMed ID: 11965581
[TBL] [Abstract][Full Text] [Related]
31. Serum Mac-2 binding protein glycosylation isomer predicts the activation of hepatic stellate cells after liver transplantation.
Yamada N; Katano T; Hirata Y; Okada N; Sanada Y; Ihara Y; Urahashi T; Ushijima K; Karasawa T; Takahashi M; Mizuta K
J Gastroenterol Hepatol; 2019 Feb; 34(2):418-424. PubMed ID: 30101431
[TBL] [Abstract][Full Text] [Related]
32. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients.
Berenguer M; Aguilera V; San Juan F; Benlloch S; Rubin A; López-Andujar R; Moya A; Pareja E; Montalva E; Yago M; de Juan M; Mir J; Prieto M
Transplantation; 2010 Dec; 90(11):1204-9. PubMed ID: 21068701
[TBL] [Abstract][Full Text] [Related]
33. Management of liver transplantation waiting list for decompensated cirrhosis in a Spanish tertiary hospital: differences between hepatitis C virus recipients and other etiologies.
Ibáñez Samaniego L; Pérez Valderas M; Fernández Yunquera A; Rincón Rodríguez D; López Baena JA; Matilla Peña A; Catalina Rodríguez MV; Clemente Ricote G; Bañares Cañizares R; Salcedo Plaza M
Transplant Proc; 2014 Nov; 46(9):3084-6. PubMed ID: 25420829
[TBL] [Abstract][Full Text] [Related]
34. Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment.
Toniutto P; Fabris C; Fumo E; Apollonio L; Caldato M; Mariuzzi L; Avellini C; Minisini R; Pirisi M
Am J Clin Pathol; 2004 Sep; 122(3):428-33. PubMed ID: 15362374
[TBL] [Abstract][Full Text] [Related]
35. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.
Guillaud O; Gurram KC; Puglia M; Lilly L; Adeyi O; Renner EL; Selzner N
Transplant Proc; 2013; 45(6):2331-6. PubMed ID: 23953545
[TBL] [Abstract][Full Text] [Related]
37. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
[TBL] [Abstract][Full Text] [Related]
38. Donor hypernatremia before procurement and early outcomes following pediatric liver transplantation.
Kaseje N; McLin V; Toso C; Poncet A; Wildhaber BE
Liver Transpl; 2015 Aug; 21(8):1076-81. PubMed ID: 25902852
[TBL] [Abstract][Full Text] [Related]
39. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.
Eurich D; Boas-Knoop S; Ruehl M; Schulz M; Carrillo ED; Berg T; Neuhaus R; Neuhaus P; Neumann UP; Bahra M
Liver Transpl; 2011 Mar; 17(3):289-98. PubMed ID: 21384511
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Fibrosis Progression Rate in Patients with Chronic Hepatitis C Genotype 4: Role of Cirrhosis Risk Score and Host Factors.
Besheer T; El-Bendary M; Elalfy H; Abd El-Maksoud M; Salah M; Zalata K; Elkashef W; Elshahawy H; Raafat D; Elemshaty W; Almashad N; Zaghloul H; El-Gilany AH; Abdel Razek AA; Abd Elwahab M
J Interferon Cytokine Res; 2017 Mar; 37(3):97-102. PubMed ID: 28068153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
